Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies (ALUR): RTW files Amendment No. 9 to Schedule 13D, reporting beneficial ownership of 4,035,142 shares, or 43.6% of the common stock.
On November 5, 2025, the RTW funds converted $5.0 million principal amount of notes into 1,492,539 shares under an amended note purchase agreement. The ownership percentages are based on 7,762,681 shares outstanding as of August 8, 2025, plus the shares issued pursuant to the November 2025 conversion notice. RTW Investments, LP and Roderick Wong report shared voting and dispositive power over 4,035,142 shares.
By entity, RTW Master Fund, Ltd. reports 2,147,254 shares (23.2%), and RTW Innovation Master Fund, Ltd. reports 1,659,241 shares (17.9%). The notes include a 9.99% beneficial ownership conversion cap, while RTW’s warrants are subject to a 4.99% blocker that can be increased to 9.99% with 61 days’ prior notice.
Allurion Technologies (ALUR): Affiliated funds managed by RTW Investments reported converting an aggregate $5.0 million principal amount of Allurion’s convertible senior secured notes into common stock at the floor conversion price of $3.35 per share on November 5, 2025. The filing identifies the reporting persons as a Director and 10% owner and indicates the form is filed by more than one reporting person.
The conversion resulted in share issuances to multiple RTW-managed entities, including 822,722 shares to RTW Master Fund and 631,954 shares to RTW Innovation. The notes bear 6.0% annual interest and mature on April 16, 2031. Remaining notes are convertible at $40.50 per share and may also be converted at additional prices at the issuer’s discretion. A 9.99% beneficial ownership limitation applies, unless a discretionary conversion is used.
Allurion Technologies, Inc. reported that Milena Alberti-Perez, a Class III director and chairperson of the Audit Committee, resigned from the board effective September 30, 2025. The company states that her resignation was not due to any disagreement with management, the board, or company operations, policies, or practices.
The filing explains that Ms. Alberti-Perez is stepping down to focus on opportunities in the media sector, including a new board role at another public company. Following her departure, the size of Allurion’s board will be reduced from nine to eight members as part of the board’s view that a smaller board can improve efficiency and reduce director compensation costs. The board is evaluating which current director will be appointed as the new Audit Committee chairperson.
Allurion Technologies amended its quarterly report to reflect a restatement and adjustments tied to a Reverse Stock Split and the closing of its Business Combination with Compute Health. The filing discloses material weaknesses in internal control over financial reporting and describes remediation steps including hiring accounting staff, implementing a new ERP, and engaging a national accounting firm.
The company completed several financing and capital transactions: a PIPE investment of $37.9 million, a Public Offering consummated July 1, 2024, amended convertible note arrangements, and revenue interest financing that pays 6.0% of annual net sales through 2026 and up to 10.0% thereafter until 2030. The Allurion Balloon sales were suspended in France and remediation is underway; the company also disclosed NYSE non-compliance and submitted a plan to regain compliance.
Allurion Technologies amended its Form 10-Q to restate prior interim financials and reflect a 1-for-25 reverse stock split effective January 3, 2025. The filing discusses the completed Business Combination with Compute Health and conversion/recapitalization mechanics that produced Allurion common stock and warrants, notes the Company completed a Public Offering on July 1, 2024, and records a $37.9 million PIPE investment. The company discloses material weaknesses in internal control over financial reporting and remediation actions underway, and reports a suspension of Allurion Balloon sales in France in August 2024. Debt and convertible note amendments, warrant conversions and derivative accounting for certain PIPE and conversion options are described.
Allurion Technologies, Inc. amended its quarterly report to reflect a reverse stock split and provides details on the previously completed Business Combination with Compute Health Acquisition Corp., related equity recapitalizations, and follow-on financing arrangements. The filing discloses a $37.9 million PIPE investment and multiple convertible note, term loan and revenue-interest financing arrangements with detailed conversion, royalty and reset provisions that could affect future dilution and cash obligations.
The company disclosed prior-period adjustments related to retroactive share restatements from the Business Combination, and identified material weaknesses in internal control over financial reporting with described remedial steps including hiring accounting staff, implementing a new ERP, additional review controls, and engagement of a national accounting firm. The filing also discusses contingent consideration valuation, warrant liabilities, and various debt modifications and covenant features.
Allurion Technologies (ALUR) amended its annual report to reflect a reverse stock split, the close of a business combination with Compute Health, and several financing and restructuring items. The filing discloses continued net operating losses and significant debt, including a $40.0 million upfront Revenue Interest Financing that requires royalty-style payments of up to 6.0% of annual net sales through 2026 and up to 10.0% thereafter through 2030. The company is restating prior financial statements and discloses material weaknesses in disclosure controls and internal control over financial reporting. The Allurion Balloon remains unapproved for commercial sale in the U.S.; the company is conducting an FDA IDE trial (AUDACITY) to support a future PMA. Operationally, Allurion reports commercialization in over 50 countries, a connected patient App and scale, an AI-powered clinic dashboard (Allurion Insights/Allurion Iris AI), and plans to expand its product label, geographic reach, and SaaS offerings. The filing lists numerous risk factors including regulatory, clinical, supply-chain, litigation, liquidity and market-acceptance risks that may materially affect results.
Allurion Technologies reported operational and financial updates alongside a restatement and remediation efforts for internal control weaknesses. The company is addressing a restatement of prior financial statements and disclosed material weaknesses in internal control over financial reporting while describing steps taken to remediate those weaknesses, including hiring experienced accounting staff, implementing a new ERP system, and engaging a national accounting firm. Management announced a strategic restructuring expected to reduce the workforce by about 70 employees (~65% of staff) with estimated severance-related charges of approximately $1.5 million. Financing activity included multiple private placements and offerings that raised net proceeds of $2.5 million (RTW private placement), $5.8 million (January 2025 offering), and $3.9 million (February 2025 offering), plus a Leavitt placement of $1.3 million. The company described amended revenue interest financing that increases payments from 6.0% up to 10.0% of annual net sales after 2027 and various conversion features tied to PIPE and RTW convertible notes. The filing discloses a pending litigation claim seeking approximately $2.5 million and details product, regulatory, and commercialization initiatives including a GLP-1 program, distribution transitions, and a planned multi-center study in Europe.
Allurion Technologies (ALUR) amended its quarterly report to reflect a prior restatement and to disclose post-business-combination corporate and financing activity. The company completed a business combination with Compute Health and applied a reverse stock split, which changed warrant and share conversion ratios. It disclosed multiple equity and warrant offerings closed in January and February 2025 that raised net proceeds of $5.8 million and $3.9 million, respectively, and additional private placements raising $2.5 million and $1.3 million. The company described amendments to a revenue interest financing agreement that increased revenue-interest rates and related derivative accounting, conversions and debt modifications, and recorded related liabilities and remeasurements. Allurion operates in ~50 countries, provides the Allurion Program and App for remote patient monitoring, and disclosed remediation steps for previously identified internal control weaknesses and an NYSE cure plan.
Allurion Technologies (ALUR) amended its annual report describing strategic, operational and financial risks tied to its post‑merger transition and commercialization of the Allurion Balloon. The company completed a Business Combination with Compute Health and various financings including a July 1, 2024 public offering that raised net proceeds of $15.2 million and multiple private placements. Allurion sells the Allurion Balloon and an AI‑powered Virtual Care Suite (VCS) in over 40 countries but the Balloon is not approved for commercial sale in the U.S. The filing discloses a restatement of prior financial statements, material weaknesses in internal controls, significant debt and revenue‑interest financing with RTW that carries contingent payment rates and covenants. The company states it has incurred losses and expects losses to continue while FDA approval, regulatory compliance, NYSE cure planning, supply, and reimbursement risks remain material.